Chiasma Pharma Raises $70M In Series E Funding

March 1, 2015 | The Israeli biopharmaceutical company Chiasma announced that it closed a $70 million Series E funding round. Rock Springs Capital and Sofinnova Ventures were new investors in the round, together with existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Chiasma hopes to use the new funds to grow its sales and marketing capabilities, as well as to prepare for the commercial launch of its product for adults with acromegaly, a rare endocrine disease, among other things. Chiasma was founded in 2001 and is headquartered in Jerusalem and Newton, Massachusetts.